Synthetic Minds | AI Just Took the Decision Seat Between You and the Drug

The Synthetic Minds newsletter offers short daily insights to get you thinking. If you enjoy it, please forward. All signals are powered by Futurwise. If you need more insights, subscribe to Futurwise and get 25% off for the first three months!

I have just launched the Intelligence Age Scorecard! It will help you understand how ready your organization is for the Intelligence Age.

Today’s topic: Health & Longevity

The Algorithm Now Decides If You're Eligible

A pancreatic cancer was visible on a CT scan three years before any human spotted it, and this week, four other algorithms quietly took their seats inside the regulator's review desk, the insurer's risk table, and the eligibility gate of a first-in-class drug.

The seat between you and your medicine is no longer empty, and no one is sure who is sitting in it.

Five health stories this week look like five different stories. They aren't.

• The FDA put AstraZeneca's mantle cell lymphoma trial and Amgen's small cell lung carcinoma trial onto a real-time data pipeline, with reviewers watching endpoints "in the cloud in real time."
• Nature Medicine published OBSCORE, a model trained on 200,000 people that displaces BMI for stratifying eighteen obesity-related complications.
• Google DeepMind released head-to-head data showing physicians preferred its AI co-clinician to existing evidence-synthesis tools across 97 of 98 primary-care queries.
• Eric Topol pointed out the paradox: the AI applications with the strongest evidence are the least deployed, while AI chatbots with no clinical guardrails reach 40 million Americans daily.
• The FDA approved Veppanu, the first PROTAC, with a mandatory companion diagnostic that turns the eligibility decision into a genomic test result.

That's the AI-in-healthcare story. Here is the signal.

Five different control points. Same direction. AI is moving inside the layer of medicine where eligibility, monitoring, and decision authority get decided, not the layer where therapies get made. The regulator's review desk. The risk-stratification table. The bedside decision. The drug eligibility gate.

Each one of those used to be a human decision under institutional governance. This week, each of them took a step toward becoming an algorithmic one.

Now watch what came with it.

Liability is being silently rerouted into model-update cycles that no hospital governance committee has the skills to audit.

Topol's paradox is the second-order effect; the soft applications scale, the evidence-backed ones do not, and malpractice law, payer audit trails, and IRB structures still assume human-bounded decisions.

This is not AI in medicine. It is AI inside the seat that decides who counts as a patient.

The question is no longer whether AI will be in healthcare. It is who is accountable when the algorithm sits between you and the drug, and which institutions have not yet noticed the seat is no longer theirs.

The Intelligence Age Scorecard

Five separate health stories this week converged on one structural shift: AI moved into the eligibility, monitoring, and decision layer of medicine. Are you still watching this curve, or should your governance, risk, and clinical leadership teams already be adapting? Take the Intelligence Age Scorecard to benchmark your readiness across all four WAVE pillars for the next two quarters, not the next decade.

If this newsletter was forwarded to you, you can sign up here.

Thank you.
Mark